Media: Press Releases | 06 November 2020
London, 6 November 2020 – International law firm Hogan Lovells has advised NYSE listed PerkinElmer, a global leader in the life sciences and diagnostics industry, on its recently announced all cash, public takeover offer for Horizon Discovery Group PLC, a leading gene editing company. The deal has a total enterprise value of approximately $368 million (£284 million) and is expected to close in the first quarter of 2021 subject to customary closing conditions.
Among other benefits, the acquisition will enable PerkinElmer to leverage its combined screening and applied genomics solutions to help propel the next phase of cell and gene research for precision medicine.
The Hogan Lovells team was led by Corporate M&A partner Tom Brassington with support from counsel Karla Dudek.
Commenting on the deal, Tom said: “We were delighted to act for PerkinElmer on this transaction.The life sciences sector remains very strong, despite the effects of COVID-19 on the global economy more generally, and helping PerkinElmer execute a transatlantic deal for a company which is on the cutting edge of what’s next in that sector played straight into the strengths of the Hogan Lovells platform.”